

BIOGRAPHICAL SKETCH			
NAME Marta Coscia, M.D., Ph. D.		POSITION TITLE Associate Professor of Hematology	
EDUCATION/TRAINING			
INSTITUTION AND LOCATION	DEGREE	YEAR(s)	FIELD OF STUDY
University of Torino	M.D.	1992-1998	Medical Sciences
University of Torino	Board certification	1998-2002	Hematology
University of Torino	Ph.D.	2005-2009	Immunology and cellular biology

### Personal Statement

I am a physician scientist with a broad background in Hematology, and a specific training and expertise in translational research. After obtaining my board certification in hematology (2002), I spent a 2-year period as Visiting Scientist at National Cancer Institute (NCI/NIH, Bethesda, MD, U.S.A.) (2002-2004), increasing my expertise on anti-tumor immunotherapy and cancer vaccines in B-cell lymphoproliferative disorders. In 2009, I obtained my PhD in Immunology and Cell Biology. In 2015 I started my own research group working on the study of the reciprocal interactions occurring between the immune system, the tumor microenvironment and cancer cells in lymphoproliferative disorders. Currently, I have a double appointment as Associate Professor of hematology in the Department of Molecular Biotechnology and Health Sciences (DBMHS) of the University of Torino and as Associate Medical Director in the Division of Hematology of the “Città della Salute e della Scienza” University Hospital of Torino. As head of the Unit on Chronic Lymphoproliferative Disorders, I am principal investigator in several translational studies as well as in clinical trials evaluating the efficacy of new therapeutic agents in chronic lymphocytic leukemia. I am lecturer and tutor on Hematology in the School of Medicine and in the School of Biotechnology, lecturer and tutor within the Master program “Stem cells in Regenerative Medicine and Cell Factory Management”, and lecturer within the PhD program in Biomedical Sciences and Oncology, at the University of Torino. I am Director of the post-graduate School of Hematology and member of the Board of the Working Party GIMEMA on chronic lymphoproliferative disorders.

### Positions and employment

- 1998-2002 Post-doctoral fellow, Post-graduate School of Hematology, Department of Medicine and Experimental Oncology, University of Torino.
- 2003-2004 Visiting Scientist hired by S.A.I.C. Inc., Experimental transplantation and Immunology Branch, National Cancer Institute, National Institute of Health, Bethesda, MA, U.S.A.

- 2007-2019 Assistant Professor, Department of molecular biotechnology and health sciences, University of Torino
- 2007- Staff physician, Division of Hematology, Città della Salute e della Scienza University Hospital of Torino - Via Genova, 3 10126, Torino.
- 2015- Head of the Laboratory of Translational Hematology, Department of Molecular Biotechnology and Health Sciences, University of Torino.
- 2015- Head of the CLL Unit, Division of Hematology, Città della Salute e della Scienza University Hospital of Torino - Via Genova, 3 10126, Torino.
- 2019- Associate Professor of Hematology, Department of Molecular Biotechnology and Health Sciences, University of Torino.
- 2020- Director of the Postgraduate School of Hematology, University of Torino

### **Other Experience and Professional Records**

- 1996-1998 Internship, Division of Hematology, University of Torino (clinical and research activity);
- 2002-2003 Research fellow, Experimental transplantation and Immunology Branch, National Cancer Institute, National Institute of Health, Bethesda, MA, U.S.A.;
- 2005-2007 Research fellow, Division of Hematology, University of Torino;
- 2011 Training Course “Future Advance in Management Expertise” - Percorso di formazione manageriale per Medici Specialisti in Oncoematologia (3 modules of 2 days each).
- 2012 Training Course “Future Advance in Management Expertise” - Percorso di formazione manageriale per Medici Specialisti in Oncoematologia (one module of 2 days).
- 2016 National Academic Qualification as Associate Professor

### **Honors and awards**

- 2004-2005 Fellowship San Giovanni Battista Hospital, Torino, Italy (clinical and research activity);
- 2005-2006 Fellowship “Fondazione Angela Bossolasco”, Torino, Italy (clinical and research activity);
- 2005 Annual AIL (Italian Association against Leukemia) “Simona Drappo” award for young researcher;
- 2006 José Carreras Foundation National award for young researchers;
- 2006-2007 Fellowship AIL (Associazione Italiana contro le leucemie- linfomi e mieloma) (clinical and research activity).
- 2020- Member of the Scientific Committee in the Master Program Stem cells in Regenerative Medicine and Cell Factory Management, University of Torino.
- 2021 Invited chairman of the oral abstract session on “Cellular immunotherapy and gene therapy - Experimental” at the EHA2021Virtual Congress (June 9-17, 2021).
- 2021- Member of the Board of the Working Party GIMEMA on chronic lymphoproliferative disorders (selected by the board of directors of the GIMEMA Foundation).

### **Teaching employments**

- 2007-2016 Lecturer on “Hematology” in the School of Medicine, University of Torino.
- 2007- Lecturer in the Post-graduate School of Hematology, University of Torino.
- 2010- Tutor within the Post-graduate School of Hematology, University of Torino.
- 2011-2015 Tutor within the Doctoral School in Life and Health Sciences, University of Torino.
- 2014- Member of the organizing committee of the Post-graduate School of Hematology, University of Torino.
- 2019- Lecturer on “Hematology” in the Biotechnology course of the University of Torino.
- 2019- Lecturer on “Hematology” in the School of Medicine, University of Torino.
- 2020- Lecturer in the Master Program II level - Stem cells in Regenerative Medicine and Cell Factory Management (Modules on CAR T-cell therapy), University of Torino.
- 2020- Lecturer in the Post-graduate School of Allergology and Clinical Immunology, University of Torino.
- 2020- Lecturer in the Post-graduate School of Anesthesiology and Intensive Care, University of Torino.
- 2021- Lecturer in the Post-graduate School of Geriatrics, University of Torino.
- 2021- Lecturer in the Post-graduate School of Radiotherapy, University of Torino.
- 2021- Lecturer within the Ph.D. Program in Biomedical Sciences and Oncology, University of Torino.

### **Clinical Research activity**

- Head of the Chronic Lymphoproliferative Disorders Unit, University Division of Hematology, Città della Salute e della Scienza University Hospital of Torino.
- Principal Investigator in >30 clinical trials investigating the role of new drugs for the treatment of patients with chronic lymphocytic leukemia.

### **Professional Societies**

- Italian Society of Hematology (SIE)
- Italian Society of Experimental Hematology (SIES)
- European Hematology Association (EHA)
- European Research Initiative on CLL (ERIC)

### **Editorial activity**

- Peer reviewer for Journal of Cellular and Molecular Medicine (IF 4,302), Cancer Immunology Immunotherapy (IF 4,225), European Journal of Hematology (IF 2,595), Frontiers in Oncology (IF 4,416), Frontiers in Immunology, Oncotarget (IF 5,168), Leukemia (IF 10,023), Haematologica (IF 9,090), Cancers (IF 6,162), British Journal of Cancer (IF 5,791), Blood Reviews (IF 6.6), Clinical and Translational Medicine (IF 7,919).
- Review Editor for Frontiers in Oncology
- Editor for the special issue entitled “CAR T-Cell Therapies in Hematologic Tumors” for the journal Frontiers in Oncology.
- Member of the editorial board of International Journal of Molecular Sciences

### **Scientific interests**

- Tumor-related immune dysfunctions and immunomodulatory properties of new targeted drugs in chronic lymphocytic leukemia

- Tumor-microenvironment interactions and mechanisms of drug resistance
- Anti-tumor immunotherapy in chronic lymphocytic leukemia, myeloma and other lymphoproliferative disorders
- Translational and clinical studies in chronic lymphocytic leukemia

## PEER-REVIEWED PUBLICATIONS

1. Perutelli F, Montalbano MC, Boccellato E, Coscia M\*, Vitale C\*. Beyond ibrutinib: novel BTK inhibitors for the treatment of chronic lymphocytic leukemia. *Curr Opin Oncol*. 2022 accepted for publication.
2. Fresa A, Autore F, Piciocchi A, Catania G, Visentin A, Tomasso A, Moretti M, Vitale C, Chiarenza A, Morelli F, Sportoletti P, Marasca R, Sapienza G, Cuccaro A, Murru R, Sanna A, Patti C, Angeletti I, Coscia M, Trentin L, Pietrasanta D, Innocenti I, Laurenti L. Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study. *Blood Adv*. 2022;6:3875-3878. doi: 10.1182/bloodadvances.2022006964.
3. Salvetti C, Vitale C, Griggio V, Drandi D, Jones R, Bonello L, Bomben R, Bragoni A, Bagnara D, Fais F, Gattei V, Cavallo F, Zamò A, Coscia M. Case Report: Sequential Development of Three Mature Lymphoid Neoplasms in a Single Patient: Clonal Relationship and Molecular Insights. *Front Oncol*. 2022;12:917115. doi: 10.3389/fonc.2022.917115.
4. Marchetti M, Vitale C, Rigolin GM, Vasile A, Visentin A, Scarfò L, Coscia M, Cuneo A. Old and New Drugs for Chronic Lymphocytic Leukemia: Lights and Shadows of Real-World Evidence. *J Clin Med*. 2022;11:2076. doi: 10.3390/jcm11082076.
5. Perutelli F, Jones R, Griggio V, Vitale C, Coscia M. Immunotherapeutic Strategies in Chronic Lymphocytic Leukemia: Advances and Challenges. *Front Oncol*. 2022;12:837531. doi: 10.3389/fonc.2022.837531.
6. Innocenti I, Reda G, Visentin A, Coscia M, Motta M, Murru R, Moia R, Gentile M, Pennese E, Quaglia FM, Albano F, Cassin R, Deodato M, Ielo C, Frustaci AM, Piciocchi A, Rughini A, Arena V, Di Sevo D, Tomasso A, Autore F, Del Poeta G, Scarfò L, Mauro FR, Tedeschi A, Trentin L, Pompili M, Foà R, Ghia P, Cuneo A, Laurenti L. Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study. *Haematologica*. 2022; doi: 10.3324/haematol.2021.280325.
7. Molica S, Giannarelli D, Visentin A, Reda G, Sportoletti P, Frustaci AM, Chiarenza A, Ciolli S, Vitale C, Laurenti L, De Paoli L, Murru R, Gentile M, Moia R, Rigolin GM, Levato L, Giordano A, Del Poeta G, Stelitano C, Deodato M, Ielo C, Noto A, Guarente V, Coscia M, Tedeschi A, Gaidano G, Cuneo A, Foa' R, Trentin L, Mauro FR. Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model. *Am J Hematol*. 2022;97:E176-E180. doi: 10.1002/ajh.26502.
8. Mauro FR, Paoloni F, Molica S, Reda G, Trentin L, Sportoletti P, Marchetti M, Pietrasanta D, Marasca R, Gaidano G, Coscia M, Stelitano C, Mannina D, Di Renzo N, Ilariucci F, Liberati AM, Orsucci L, Re F, Tani M, Musuraca G, Gottardi D, Zinzani PL,

- Gozzetti A, Molinari A, Gentile M, Chiarenza A, Laurenti L, Varettoni M, Ibatìci A, Murru R, Ruocco V, Del Giudice I, De Propriis MS, Della Starza I, Raponi S, Nanni M, Fazi P, Neri A, Guarini A, Rigolin GM, Piciocchi A, Cuneo A, Foà R. Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study. *Cancers (Basel)*. 2021;14:207. doi: 10.3390/cancers14010207.
9. Visentin A, Mauro FR, Cibien F, Vitale C, Reda G, Fresa A, Ciolli S, Pietrasanta D, Marchetti M, Murru R, Gentile M, Rigolin GM, Quaglia FM, Scarfò L, Sportoletti P, Pravato S, Piazza F, Coscia M, Laurenti L, Molica S, Foà R, Cuneo A, Trentin L. Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study. *Am J Hematol*. 2022;97:E95-E99. doi: 10.1002/ajh.26437.
  10. Chatzikonstantinou T, Kapetanakis A, Scarfò L, Karakatsoulis G, Allsup D, Cabrero AA, Andres M, Antic D, Baile M, Baliakas P, Bron D, Capasso A, Chatzileontiadou S, Cordoba R, Correa JG, Cuéllar-García C, De Paoli L, De Paolis MR, Del Poeta G, Demosthenous C, Dimou M, Donaldson D, Doubek M, Efstathopoulou M, Eichhorst B, El-Ashwah S, Enrico A, Espinet B, Farina L, Ferrari A, Foglietta M, Frederiksen H, Fürstenau M, García-Marco JA, García-Serra R, Gentile M, Gimeno E, Glenthøj A, Gomes da Silva M, Gutwein O, Hakobyan YK, Herishanu Y, Hernández-Rivas JÁ, Herold T, Innocenti I, Itchaki G, Jaksic O, Janssens A, Kalashnikova OB, Kalicińska E, Karlsson LK, Kater AP, Kersting S, Labrador J, Lad D, Laurenti L, Levin MD, Lista E, Lopez-Garcia A, Malerba L, Marasca R, Marchetti M, Marquet J, Mattsson M, Mauro FR, Milosevic I, Mirás F, Morawska M, Motta M, Munir T, Murru R, Niemann CU, Rodrigues RN, Olivieri J, Orsucci L, Papaioannou M, Pavlovsky MA, Piskunova I, Popov VM, Quaglia FM, Quaresmini G, Qvist K, Reda G, Rigolin GM, Ruchlemer R, Saghunyan G, Shrestha A, Šimkovič M, Špaček M, Sportoletti P, Stanca O, Stavroyianni N, Tadmor T, Te Raa D, Tonino SH, Trentin L, Van Der Spek E, van Gelder M, van Kampen R, Varettoni M, Visentin A, Vitale C, Wasik-Szczepanek E, Wróbel T, San Segundo LY, Yassin M, Coscia M, Rambaldi A, Montserrat E, Foà R, Cuneo A, Stamatopoulos K, Ghia P. COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. *Leukemia*. 2021;1–11. doi: 10.1038/s41375-021-01450-8.
  11. D'Arena G, Vitale C, Coscia M, Lamorte D, Pietrantonio G, Perutelli F, D'Auria F, Statuto T, Valvano L, Tomasso A, Griggio V, Jones R, Mansueto G, Villani O, D'Agostino S, Viglioglia V, De Feo V, Calapai F, Mannucci C, Sgambato A, Efremov DG, Laurenti L. CD200 Baseline Serum Levels Predict Prognosis of Chronic Lymphocytic Leukemia. *Cancers*. 2021; 13:4239. doi: 10.3390/cancers13164239.
  12. Tedeschi A, Frustaci AM, Mauro FR, Chiarenza A, Coscia M, Ciolli S, Reda G, Laurenti L, Varettoni M, Murru R, Baratè C, Sportoletti P, Greco A, Borella C, Rossi V, Deodato M, Biagi A, Zamproga G, Pelle AC, Lapietra G, Vitale C, Morelli F, Cassin R, Fresa A, Cavalloni C, Postorino M, Lelo C, Cairoli R, Di Raimondo F, Montillo M, and Del Poeta G. Do age, fitness and concomitant medications influence management and outcomes of CLL patients treated with ibrutinib? *Blood Advances* 2021, Accepted for publication.
  13. Vitale C, Boccellato E, Comba L, Jones R, Perutelli F, Griggio V, Coscia M. Impact of Immune Parameters and Immune Dysfunctions on the Prognosis of Patients with

Chronic Lymphocytic Leukemia. *Cancers (Basel)*. 2021;13:3856. doi: 10.3390/cancers13153856.

14. Cuneo A, Rigolin GM, Coscia M, Quaresmini G, Scarfò L, Mauro FR, Motta M, Quaglia FM, Trentin L, Ferrario A, Laurenti L, Reda G, Ferrari A, Pietrasanta D, Sportoletti P, Re F, De Paoli L, Foglietta M, Giordano A, Marchetti M, Farina L, Del Poeta G, Varettoni M, Chiurazzi F, Marasca R, Malerba L, Ibatìci A, Tisi MC, Stefoni V, Leone M, Baratè C, Olivieri J, Murru R, Gentile M, Sanna A, Gozzetti A, Gattei V, Gottardi D, Derenzini E, Levato L, Orsucci L, Penna G, Chiarenza A, Foà R. Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report. *Hematol Oncol*. 2021 Jul 13. doi: 10.1002/hon.2899. [Epub ahead of print].
15. Mauro FR, Giannarelli D, Visentin A, Reda G, Sportoletti P, Frustaci AM, Chiarenza A, Ciolli S, Vitale C, Laurenti L, De Paoli L, Murru R, Gentile M, Rigolin GM, Levato L, Giordano A, Del Poeta G, Stelitano C, Ielo C, Noto A, Guarente V, Molica S, Coscia M, Tedeschi A, Gaidano G, Cuneo A, Foà R, Martelli M, Girmenia C, Gentile G, Trentin L. Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. *Cancers (Basel)*. 2021;13:3240. doi: 10.3390/cancers13133240.
16. Vitale C, Griggio V, Riganti C, Todaro M, Kopecka J, Jones R, Salvetti C, Boccellato E, Perutelli F, Voena C, Godio L, Boccadoro M, Coscia M. Targeting HIF-1 $\alpha$  Regulatory Pathways as a Strategy to Hamper Tumor-Microenvironment Interactions in CLL. *Cancers (Basel)*. 2021;13:2883. doi: 10.3390/cancers13122883.
17. Morabito F, Del Poeta G, Mauro FR, Reda G, Sportoletti P, Laurenti L, Coscia M, Herishanu Y, Bossio S, Varettoni M, Murru R, Chiarenza A, Visentin A, Condoluci A, Moia R, Pietrasanta D, Loseto G, Consoli U, Scortechini I, Recchia AG, Rossi FM, Zucchetto A, Al-Janazreh H, Martino EA, Vigna E, Tripepi G, D'Arrigo G, Galimberti S, Rago A, Angeletti I, Biagi A, Del Giudice I, Bomben R, Neri A, Fronza G, Cutrona G, Jaksic O, Olivieri J, Rossi D, Di Raimondo F, Cuneo A, Gaidano G, Polliack A, Trentin L, Foà R, Ferrarini M, Gattei V, Gentile M. TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases. *Am J Hematol*. 2021 ;96:E306-E310. doi: 10.1002/ajh.26235.
18. Morabito F, Tripepi G, Del Poeta G, Mauro FR, Reda G, Sportoletti P, Laurenti L, Coscia M, Herishanu Y, Bossio S, Varettoni M, Murru R, Chiarenza A, Visentin A, Condoluci A, Moia R, Pietrasanta D, Loseto G, Consoli U, Scortechini I, Rossi FM, Zucchetto A, Al-Janazreh H, Vigna E, Martino EA, Cassin R, D Arrigo G, Galimberti S, Rago A, Angeletti I, Biagi A, Del Giudice I, Bomben R, Neri A, Fronza G, Monti P, Menichini P, Olivieri J, Cutrona G, Rossi D, Cuneo A, Di Raimondo F, Gaidano G, Polliack A, Trentin L, Foà R, Ferrarini M, Gattei V, Gentile M. Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials. *Am J Hematol*. 2021;96:E269-E272. doi: 10.1002/ajh.26201.
19. Dogliotti I, Ragaini S, Vassallo F, Boccellato E, De Luca G, Perutelli F, Boccomini C, Clerico M, Botto B, Grimaldi D, Orsucci L, Ferrero S, Vitale C, Ferrero D, Coscia M, Cavallo F. Real Life Use of Bendamustine in Elderly Patients with Lymphoid Neoplasia. *J Pers Med*. 2021;11:249. doi: 10.3390/jpm11040249.

20. Rigolin GM, Cavazzini F, Piciocchi A, Arena V, Visentin A, Reda G, Zamprogna G, Cibien F, Vitagliano O, Coscia M, Farina L, Gaidano G, Murru R, Varettoni M, Paolini R, Sportoletti P, Pietrasanta D, Molinari AL, Quaglia FM, Laurenti L, Marasca R, Marchetti M, Mauro FR, Crea E, Vignetti M, Gentile M, Montillo M, Foà R, Cuneo A; GIMEMA group. Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia outside of clinical trials. A report of the GIMEMA WORKING GROUP. *Hematol Oncol.* 2021;39(3):326-335. doi: 10.1002/hon.2861.
21. Vitale C, Salvetti C, Griggio V, Porrizzo M, Schiattone L, Zamprogna G, Visentin A, Vassallo F, Cassin R, Rigolin GM, Murru R, Laurenti L, Rivela P, Marchetti M, Pennese E, Gentile M, Boccellato E, Perutelli F, Montalbano MC, De Paoli L, Reda G, Orsucci L, Trentin L, Cuneo A, Tedeschi A, Scarfò L, Gaidano G, Mauro FR, Foà R, Boccadoro M, Coscia M. Pre-existing and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs. *Blood* 2021;137(25):3507-3517. doi: 10.1182/blood.2020008201.
22. Morabito F, Tripepi G, Del Poeta G, Mauro FR, Reda G, Sportoletti P, Laurenti L, Coscia M, Herishanu Y, Varettoni M, Murru R, Chiarenza A, Visentin A, Condoluci A, Moia R, Pietrasanta D, Loseto G, Consoli U, Scortechini I, Rossi FM, Zucchetto A, Vigna E, Martino EA, Mendicino F, Botta C, Caracciolo D, Cassin R, D'Arrigo G, Galimberti S, Rago A, Angeletti I, Biagi A, Del Giudice I, Bomben R, Neri A, Fronza G, Cutrona G, Rossi D, Di Raimondo F, Cuneo A, Gaidano G, Polliack A, Trentin L, Foà R, Ferrarini M, Gattei V, Gentile M. Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study. *Am J Hematol.* 2021 May 1;96(5):E168-E171. doi: 10.1002/ajh.26127.
23. Fürstenau M, Fink AM, Schilhabel A, Weiss J, Robrecht S, Eckert R, de la Serna J, Crespo M, Coscia M, Vitale C, Böttcher S, Weppner G, Ritgen M, Stilgenbauer S, Tausch E, Fischer K, Hallek M, Eichhorst B, Brüggemann M, Herling CD. B-cell Acute Lymphoblastic Leukemia in Patients with Chronic Lymphocytic Leukemia Treated with Lenalidomide. *Blood.* 2021;137(16):2267-2271. doi: 10.1182/blood.2020008609..
24. Morabito F, Tripepi G, Del Poeta G, Mauro FR, Reda G, Sportoletti P, Laurenti L, Coscia M, Herishanu Y, Bossio S, Varettoni M, Murru R, Chiarenza A, Visentin A, Condoluci A, Moia R, Pietrasanta D, Loseto G, Consoli U, Scortechini I, Rossi FM, Zucchetto A, Al-Janazreh H, Vigna E, Martino EA, Mendicino F, Cassin R, D'Arrigo G, Galimberti S, Rago A, Angeletti I, Biagi A, Del Giudice I, Bomben R, Neri A, Fronza G, Monti P, Menichini P, Cutrona G, Jaksic O, Rossi D, Di Raimondo F, Cuneo A, Gaidano G, Polliack A, Trentin L, Foà R, Ferrarini M, Gattei V, Gentile M. Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases. *Eur J Haematol.* 2021 Apr;106(4):493-499. doi: 10.1111/ejh.13573.
25. Mauro FR, Giannarelli D, Galluzzo DM, Vitale C, Visentin A, Riemma C, Rosati S, Porrizzo M, Pepe S, Gentile M, Coscia M, Trentin L, Micozzi A, Gentile G, Baroncelli S. Response to conjugate pneumococcal vaccine (PCV-13) in patients with chronic lymphocytic leukemia (CLL). *Leukemia,* 2021;35:737-746. doi: 10.1038/s41375-020-0884-z. Epub 2020 Jun 17.
26. Gentile M, Morabito F, Del Poeta G, Mauro FR, Reda G, Sportoletti P, Laurenti L, Coscia M, Herishanu Y, Recchia AG, Varettoni M, Murru R, Chiarenza A, Condoluci A, Moia R, Pietrasanta D, Loseto G, Consoli U, Scortechini I, Rossi FM, Zucchetto A,

- Fratlicelli V, Vigna E, Botta C, Tripepi G, Arrigo G, Rago A, Angeletti I, Biagi A, Del Giudice I, Bomben R, Rigolin GM, Rossi D, Di Raimondo F, Gaidano G, Polliack A, Cuneo A, Foà R, Gattei V. Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study. *Leukemia*. 2021;35:235-238. doi: 10.1038/s41375-020-0833-x.
27. Griggio V, Perutelli F, Salvetti C, Boccellato E, Boccadoro M, Vitale C, Coscia M. Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia. *Front Immunol*. 2020;11:594556. doi: 10.3389/fimmu.2020.594556.
  28. Coscia M, Bruno B, Neelapu S. Editorial: CAR T-Cell Therapies in Hematologic Tumors. *Front Oncol*. 2020;10:588134. doi: 10.3389/fonc.2020.588134.
  29. Cuneo A, Mato AR, Rigolin GM, Piciocchi A, Gentile M, Laurenti L, Allan JN, Pagel JM, Brander DM, Hill BT, Winter A, Lamanna N, Tam CS, Jacobs R, Lansigan F, Barr PM, Shadman M, Skarbnik AP, Pu JJ, Sehgal AR, Schuster SJ, Shah NN, Ujjani CS, Roeker L, Orlandi EM, Billio A, Trentin L, Spacek M, Marchetti M, Tedeschi A, Ilariucci F, Gaidano G, Doubek M, Farina L, Molica S, Di Raimondo F, Coscia M, Mauro FR, de la Serna J, Medina Perez A, Ferrarini I, Cimino G, Cavallari M, Cucci R, Vignetti M, Foà R, Ghia P; GIMEMA, European Research Initiative (ERIC) on CLL, US study group. Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. *Cancer Med*. 2020 ;9(22):8468-8479. doi: 10.1002/cam4.3470.
  30. Gentile M, Martino EA, Visentin A, Coscia M, Reda G, Sportoletti P, Mauro FR, Laurenti L, Varettoni M, Murru R, Chiarenza A, Vigna E, Mendicino F, Lucia E, Bossio S, Recchia AG, Moia R, Pietrasanta D, Loseto G, Consoli U, Scortechini I, Rossi FM, Zucchetto A, Al-Janazreh H, Vitale C, Tripepi G, D'Arrigo G, Angeletti I, Bomben R, Neri A, Cutrona G, Fronza G, Di Raimondo F, Gaidano G, Cuneo A, Foà R, Ferrarini M, Trentin L, Gattei V, Morabito F. Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib-rituximab. *Blood Cancer J*. 2020;10:92. doi: 10.1038/s41408-020-00358-3.
  31. Apolito V, Giaccone L, Ferrero S, Larocca A, Cavallo F, Coscia M, Beggiato E, Butera S, Martella F, Dainese C, Cetani G, Scaldaferrì M, Cattel F, Boccadoro M, Ferrero D, Bruno B, Cerrano M. Netupitant-palonosetron to prevent chemotherapy-induced nausea and vomiting in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation. *Ann Hematol*. 2020;99:2197-2199. doi: 10.1007/s00277-020-04180-6.
  32. Farina L, Barretta F, Scarfò L, Bruno B, Patriarca F, Frustaci AM, Coscia M, Salvetti C, Quaresmini G, Fanin R, Onida F, Magagnoli M, Zallio F, Vallisa D, Reda G, Ferrario A, Corradini P, Montillo M. Refractory and 17p-deleted chronic lymphocytic leukemia: improving survival with pathway inhibitors and allogeneic stem cell transplantation. *Biol Blood Marrow Transplant*. 2020;26:e256-e262. doi: 10.1016/j.bbmt.2020.06.032.
  33. Porrizzo M, Nicolai E, Riminucci M, Vitale C, Coscia M, De Paoli L, Rago A, Buscicchio G, Maestrini G, Ligia S, Di Prima A, Corsi A, Caronna R, Gaidano G, Mauro FR. Prognostic Significance of PET/CT in Patients with Chronic Lymphocytic



Leukemia (CLL) Treated with Frontline Chemoimmunotherapy. *Cancers (Basel)*. 2020;12:1773. doi: 10.3390/cancers12071773.

34. Scarfò L, Chatzikonstantinou T, Rigolin GM, Quaresmini G, Motta M, Vitale C, Garcia-Marco JA, Hernández-Rivas JÁ, Mirás F, Baile M, Marquet J, Niemann CU, Reda G, Munir T, Gimeno E, Marchetti M, Quaglia FM, Varettoni M, Delgado J, Iyengar S, Janssens A, Marasca R, Ferrari A, Cuéllar-García C, Itchaki G, Špaček M, De Paoli L, Laurenti L, Levin MD, Lista E, Mauro FR, Šimkovič M, Van Der Spek E, Vandenberghe E, Trentin L, Wasik-Szczepanek E, Ruchlemer R, Bron D, De Paolis MR, Del Poeta G, Farina L, Foglietta M, Gentile M, Herishanu Y, Herold T, Jaksic O, Kater AP, Kersting S, Malerba L, Orsucci L, Popov VM, Sportoletti P, Yassin M, Pocali B, Barna G, Chiarenza A, Dos Santos G, Nikitin E, Andres M, Dimou M, Doubek M, Enrico A, Hakobyan Y, Kalashnikova O, Ortiz Pareja M, Papaioannou M, Rossi D, Shah N, Shrestha A, Stanca O, Stavroyianni N, Strugov V, Tam C, Zdrengeha M, Coscia M, Stamatopoulos K, Rossi G, Rambaldi A, Montserrat E, Foà R, Cuneo A, Ghia P. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. *Leukemia*. 2020;34:2354-2363. doi: 10.1038/s41375-020-0959-x.
35. Cerrano M, Ruella M, Perales M, Vitale C, Faraci G, Giaccone L, Coscia M, Maloy M, Sanchez-Escamilla M, Elsabah H, Fadul A, Maffini E, Pittari G, Bruno B. The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research into Clinical Practice. *Front Immunol*. 2020;11:888. doi: 10.3389/fimmu.2020.00888. eCollection 2020.
36. Herishanu Y, Shaulov A, Fineman R, Bašić-Kinda S, Aviv A, Wasik-Szczepanek E, Jaksic O, Zdrengeha M, Greenbaum U, Mandac I, Simkovic M, Morawska M, Benjamini O, Spacek M, Nemets A, Bairey O, Trentin L, Ruchlemer R, Laurenti L, Stanca Ciocan O, Doubek M, Shvidel L, Dali N, Mirás F, De Meûter A, Dimou M, Mauro FR, Coscia M, Bumbea H, Szász R, Tadmor T, Gutwein O, Gentile M, Scarfò L, Tedeschi A, Sportoletti P, Gimeno Vázquez E, Marquet J, Assouline S, Papaioannou M, Braester A, Levato L, Gregor M, Rigolin GM, Loscertales J, Medina Perez A, Nijziel MR, Popov VM, Collado R, Slavutsky I, Itchaki G, Ringelstein S, Goldschmidt N, Perry C, Levi S, Polliack A, Ghia P. Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group. *Am J Hematol*. 2020 Jun;95(6):604-611. *Am J Hematol*. 2020;95:604-611. doi: 10.1002/ajh.25766.
37. Mauro FR, Molica S, Soddu S, Ilariucci F, Coscia M, Zaja F, Angelucci E, Re F, Liberati AM, Tedeschi A, Reda G, Pietrasanta D, Gozzetti A, Battistini R, Del Poeta G, Musolino C, Nanni M, Piciocchi A, Vignetti M, Neri A, Albano F, Cuneo A, Del Giudice I, Della Starza I, De Propriis MS, Raponi S, Guarini AR, Foà R. High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2). *Haematologica*. 2020;105:235705. doi: 10.3324/haematol.2019.235705.
38. Vitale C, Montalbano MC, Salvetti C, Boccellato E, Griggio V, Boccadoro M, Coscia M. Autoimmune Complications in Chronic Lymphocytic Leukemia in the Era of Targeted Drugs. *Cancers (Basel)*. 2020;12:282. doi: 10.3390/cancers12020282.

39. Griggio V, Vitale C, Todaro M, Riganti C, Kopecka J, Salvetti C, Bomben R, Bo MD, Magliulo D, Rossi D, Pozzato G, Bonello L, Marchetti M, Omedè P, Kodipad AA, Laurenti L, Del Poeta G, Mauro FR, Bernardi R, Zenz T, Gattei V, Gaidano G, Foà R, Massaia M, Boccadoro M, Coscia M. HIF-1 $\alpha$  is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia. *Haematologica*. 2020;105:1042-1054. doi: 10.3324/haematol.2019.217430.
40. Arruga F, Bracciamà V, Vitale N, Vaisitti T, Gizzi K, Yeomans A, Coscia M, D'Arena G, Gaidano G, Allan JN, Furman RR, Packham G, Forconi F, Deaglio S. Bidirectional linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and in Richter's syndrome: therapeutic implications. *Leukemia*. 2020;34:462-477. doi: 10.1038/s41375-019-0571-0.
41. Diop F, Moia R, Favini C, Spaccarotella E, De Paoli L, Bruscaggini A, Spina V, Terzi-di-Bergamo L, Arruga F, Tarantelli C, Deambrogi C, Favini S, Sagiraju S, Jabangwe C, Kodipad AA, Peroni D, Mauro FR, Del Giudice I, Forconi F, Cortelezzi A, Zaja F, Bomben R, Rossi FM, Visco C, Chiarenza A, Rigolin GM, Marasca R, Coscia M, Perbellini O, Tedeschi A, Laurenti L, Motta M, Donaldson D, Weir P, Mills K, Thornton P, Lawless S, Bertoni F, Del Poeta G, Cuneo A, Follenzi A, Gattei V, Boldorini RL, Catherwood M, Deaglio S, Foà R, Gaidano G, Rossi D. Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia. *Haematologica* 2020;105(2):448-456.
42. Visentin A, Deodato M, Mauro FR, Autore F, Reda G, Vitale C, Molica S, Rigolin GM, Piazza F, Cesini L, Tedeschi A, Laurenti L, Cassin R, Coscia M, Cuneo A, Foà R, Semenzato G, Trentin L. A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia. *Hematol Oncol*. 2019;37:508-512. doi: 10.1002/hon.2655.
43. Autore F, Strati P, Innocenti I, Corrente F, Trentin L, Cortelezzi A, Visco C, Coscia M, Cuneo A, Gozzetti A, Mauro FR, Frustaci AM, Gentile M, Morabito F, Molica S, Falcucci P, D'Arena G, Murru R, Vincelli D, Efremov DG, Ferretti A, Rigolin GM, Vitale C, Tisi MC, Reda G, Visentin A, Sica S, Foà R, Ferrajoli A, Laurenti L. Elevated Lactate Dehydrogenase Has Prognostic Relevance in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12. *Cancers (Basel)*. 2019;11:896. doi: 10.3390/cancers11070896.
44. D'Arena G, Valvano L, Vitale C, Coscia M, Statuto T, Bellesi S, Lamorte D, Musto P, Laurenti L, D'Auria F. CD200 and prognosis in chronic lymphocytic leukemia: conflicting results. *Leuk Res* 2019;83:106169. doi: 10.1016/j.leukres.2019.106169..
45. Innocenti I, Morelli F, Autore F, Piciocchi A, Frustaci A, Mauro FR, Schiattone L, Trentin L, Del Poeta G, Reda G, Rigolin GM, Ibatci A, Ciolli S, Coscia M, Sportoletti P, Murru R, Levato L, Gentile M, D'Arena G, Villa MR, Fontana R, Efremov D, Tedeschi A, Scarfò L, Cuneo A, Foà R, Laurenti L. Venetoclax in CLL patients who progress after B-cell Receptor inhibitor treatment: a retrospective multicentric Italian experience. *Br J Haematol* 2019; 187(1):e8-e11. doi: 10.1111/bjh.16123.
46. Coscia M, Vitale C, Cerrano M, Maffini E, Giaccone L, Boccadoro M, Bruno B. Adoptive immunotherapy with CAR modified T cells in cancer: current landscape and future perspectives. *Front Biosci (Landmark Ed)* 2019;24:1284-1315. doi: 10.2741/4780.

47. Italian Association for the Study of the Liver (AISF), Angelucci E, Astegiano M, Baratelli C, Biancone L, Bironzo P, Brancaccio G, Brunetto MR, Bruno R, Burra P, Cabras MG, Caraceni P, Chialà C, Clemente MG, Colli A, Daniele B, De Gasperi E, Di Marco V, Ditto MC, Fagioli S, Ferri C, Gaeta GB, Grossi PA, Imperatrice B, Lampertico P, Macaluso FS, Madonia S, Marignani M, Mazzarelli C, Mella A, Missale G, Parisi S, Pasulo L, Puoti M, Rendina M, Ribaldone D, Rossi G, Toniutto P, Tucci A, Vajro P, Viganò M, Volpes R, Zignego AL, Giannini EG, Miele L, Russo FP, Petta S, Bonora S, Brignardello E, Busca A, Cariti G, Cavallo F, Conforti M, Coscia M, Craxì A, Curci D, Cusinato S, Di Maio M, Valle RD, Fusaro E, Giacardi A, Giaccione L, Lagget M, Libertucci D, Minutolo R, Montrucchio G, Orlando A, Orsucci L, Pasquina C, Pera A, Peroni CL, Pirisi M, Racca P, Riccardini F, Rizzetto M, Salizzoni M, Salomone M, Saracco GM, Scaglione L, Torre G, Tozzi R, Vitolo U, Verme G. AISF position paper on HCV in immunocompromised patients. *Digestive and Liver Disease* 2019;51:10-23. doi:10.1016/j.dld.2018.09.022.
48. Gounari M, Ntoufa S, Gerousi M, Vilia MG, Moysiadis T, Kotta K, Papakonstantinou N, Scarfò L, Agathangelidis A, Fonte E, Ranghetti P, Nenou A, Xochelli A, Coscia M, Tedeschi A, Stavroyianni N, Muzio M, Stamatopoulos K, Ghia P. Dichotomous Toll-like receptor responses in chronic lymphocytic leukemia patients under ibrutinib treatment. D'Arena G, Valvano L, Vitale C, Coscia M, Statuto T, Bellesi S, Lamorte D, Musto P, Laurenti L, D'Auria F. CD200 and prognosis in chronic lymphocytic leukemia: Conflicting results. *Leuk Res.* 2019 Jun 11;83:106169. doi: 10.1016/j.leukres.2019.106169.
49. D'Arena G, Vitale C, Coscia M, D'Auria F, Bellesi S, Topini G, Panichi V, Valvano L, Statuto T, Corrente F, Laurenti L. External validation of the accuracy of 'CLLflow score'. *J Investig Med.* 2018;66:e6. doi: 10.1136/jim-2018-000832.
50. Gentile M, Shanafelt TD, Mauro FR, Reda G, Rossi D, Laurenti L, Del Principe MI, Cutrona G, Angeletti I, Coscia M, Herishanu Y, Chiarenza A, Molica S, Ciolli S, Goldschmidt N, Angrilli F, Giordano A, Rago A, Bairey O, Tripepi G, Chaffee KG, Sameer PA, Vigna E, Zirlik K, Shvidel L, Innocenti I, Recchia AG, Di Raimondo F, Del Poeta G, Cortelevzi A, Neri A, Ferrarini M, Gaidano G, Kay NE, Polliack A, Foà R, Morabito F. Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment. *Eur J Haematol.* 2018. doi:10.1111/ejh.13149. [Epub ahead of print].
51. Cuneo A, Follows G, Rigolin GM, Piciocchi A, Tedeschi A, Trentin L, Medina Perez A, Coscia M, Laurenti L, Musuraca G, Farina L, Rivas Delgado A, Orlandi EM, Galieni P, Mauro FR, Visco C, Amendola A, Billio A, Marasca R, Chiarenza A, Meneghini V, Ilariucci F, Marchetti M, Molica S, Re F, Gaidano G, Gonzalez M, Forconi F, Ciolli S, Cortelevzi A, Montillo M, Smolej L, Schuh A, Eyre TA, Kennedy B, Bowles KM, Vignetti M, de la Serna J, Moreno C, Foà R, Ghia P. Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study. *Haematologica.* 2018;103:1209-1217. doi: 10.3324/haematol.2018.189837.
52. D'Arena G, Vitale C, Rossi G, Coscia M, Omedè P, D'Auria F, Statuto T, Valvano L, Ciolli S, Gilestro M, Molica S, Bellesi S, Giuseppe T, Valentina P, Autore F, Innocenti I, Musto P, Deaglio S, Laurenti L, Del Vecchio L. CD200 included in a 4-marker modified Matutes score provides optimal sensitivity and specificity for the diagnosis of chronic

lymphocytic leukaemia. *Hematol Oncol*. 2018. doi: 10.1002/hon.2510. [Online ahead of print].

53. Gentile M, Shanafelt TD, Reda G, Mauro FR, Zirlik K, Ciolli S, Laurenti L, Del Principe MI, Rossi D, Di Renzo N, Molica S, Angrilli F, Coscia M, Chiarenza A, Giordano A, Cutrona G, Chaffee KG, Parikh SA, Uccello G, Innocenti I, Tripepi G, D'Arrigo G, Vigna E, Recchia AG, Herishanu Y, Shvidel L, Tadmor T, Cortelezzi A, Del Poeta G, Gaidano G, Di Raimondo F, Neri A, Ferrarini M, Foà R, Polliack A, Morabito F. Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab. *Leukemia*. 2018 Aug;32(8):1869-1873. doi: 10.1038/s41375-018-0100-6.
54. D'Arena G, Vitale C, Coscia M, Festa A, Di Minno NMD, De Feo V, Caraglia M, Calapai G, Laurenti L, Musto P, Di Minno G, Fenoglio D. Regulatory T Cells and Their Prognostic Relevance in Hematologic Malignancies. *J Immunol Res*. 2017;2017:1832968.
55. D'Arena G, Vitale C, Perbellini O, Coscia M, La Rocca F, Ruggieri V, Visco C, Di Minno NMD, Innocenti I, Pizza V, Deaglio S, Di Minno G, Giudice A, Calapai G, Musto P, Laurenti L, Iorio EL. Prognostic relevance of oxidative stress measurement in chronic lymphocytic leukaemia. *Eur J Haematol*. 2017; 99:306-314.
56. Laurenti L, Innocenti I, Autore F, Ciolli S, Mauro FR, Mannina D, Del Poeta G, D'Arena G, Massaia M, Coscia M, Molica S, Pozzato G, Efremov DG, Vannata B, Marasca R, Galieni P, Cuneo A, Orlando S, Piciocchi A, Boncompagni R, Vincelli D, Liberati AM, Russo F, Foa' R. Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification. *Haematologica*. 2017;102:e352-e355.
57. Ghione P, Genuardi E, Rossi D, Drandi D, Mantoan B, Barbero D, Bernocco E, Monitillo L, Cerri M, Ruggeri M, Omede P, Deambrogi C, De Paoli L, Passera R, Coscia M, Cavallo F, Massaia M, Boccadoro M, Gaidano G, Ladetto M, Ferrero S. Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: evidences from long term follow-up. *Br J Haematol*. 2018;181:693-695.
58. Vitale C, Griggio V, Todaro M, Salvetti C, Boccadoro M, Coscia M. Magic pills: new oral drugs to treat chronic lymphocytic leukemia. *Expert Opin Pharmacother*. 2017;18(4):411-425.
59. Arruga F, Gizdic B, Bologna C, Cignetto S, Buonincontri R, Serra S, Vaisitti T, Gizzi K, Vitale N, Garaffo G, Mereu E, Diop F, Neri F, Incarnato D, Coscia M, Allan J, Piva R, Oliviero S, Furman RR, Rossi D, Gaidano G, Deaglio S. Mutations in NOTCH1 PEST-domain orchestrate CCL19-driven homing of Chronic Lymphocytic Leukemia cells by modulating the tumor suppressor gene DUSP22. *Leukemia*. 2017;31(9):1882-1893.
60. Griggio V, Mandili G, Vitale C, Capello M, Macor P, Serra s, Castella B, Peola S, Foglietta M, Drandi D, Omedé P, Sblattero D, Cappello P, Chiarle R, Deaglio S, Boccadoro M, Novelli F, Massaia M and Coscia M. Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia. *Oncotarget*. 2017; 8:3274-3288.

61. Serra S, Vaisitti T, Audrito V, Bologna C, Buonincontri R, Chen SS, Brusa D, Coscia M, Jaksic O, Inghirami G, Rossi D, Furman RR, Robson SC, Gaidano G, Chiorazzi N, Deaglio S. Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment. *Blood Advances*. 2016; 1:47-61.
62. Gentile M, Zirlik K, Ciolli S, Mauro FR, Di Renzo N, Mastrullo L, Angrilli F, Molica S, Tripepi G, Giordano A, Di Raimondo F, Selleri C, Coscia M, Musso M, Orsucci L, Mannina D, Rago A, Giannotta A, Ferrara F, Herishanu Y, Shvidel L, Tadmor T, Scortechini I, Ilariucci F, Murru R, Guarini A, Musuraca G, Mineo G, Vincelli I, Arcari A, Tarantini G, Caparrotti G, Chiarenza A, Levato L, Villa MR, De Paolis MR, Zinzani PL, Polliack A, Morabito F. Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials. *Eur J Cancer*. 2016; 60:154-65.
63. Laurenti L, Autore F, Innocenti I, D'Arena G, Coscia M, Mondello P, Chiusolo P, Bellesi S, Efremov DG, Sica S, Mauro FR. Autoimmune hemolytic anemia during bendamustine plus rituximab treatment in CLL patients: multicenter experience. *Leuk Lymphoma*. 2016; 27:1-3.
64. Bologna C, Buonincontri R, Serra S, Vaisitti T, Audrito V, Brusa D, Pagnani A, Coscia M, D'Arena G, Mereu E, Piva R, Furman RR, Rossi D, Gaidano G, Terhorst C, Deaglio S. SLAMF1 regulation of chemotaxis and autophagy determines CLL patient response. *J Clin Invest*. 2016; 126:181-94.
65. Castella B, Foglietta M, Sciancalepore P, Rigoni M, Coscia M, Griggio V, Vitale C, Ferracini R, Saraci E, Omedé P, Riganti C, Palumbo A, Boccadoro M, Massaia M. Anergic bone marrow V $\gamma$ 9V $\delta$ 2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma. *Oncoimmunology*. 2015; 4:e1047580.
66. Tedeschi A, Rossi D, Motta M, Quaresmini G, Rossi M, Coscia M, Anastasia A, Rossini F, Cortelezzi A, Nador G, Scarfò L, Cairoli R, Frustaci AM, Dalceggio D, Picardi P, De Paoli L, Orlandi E, Rambaldi A, Massaia M, Gaidano G, Montillo M. A phase II multi-center trial of Pentostatine plus Cyclophosphamide with Ofatumumab in older previously untreated chronic lymphocytic leukemia patients. *Haematologica*. 2015. 100:501-4.
67. Rigoni M, Riganti C, Vitale C, Griggio V, Campia I, Robino M, Foglietta M, Castella B, Sciancalepore P, Buondonno I, Drandi D, Ladetto M, Boccadoro M, Massaia M, Coscia M. Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells. *Oncotarget*. 2015; 6:29833-46.
68. Rossi D, Terzi-di-Bergamo L, De Paoli L, Cerri M, Ghilardi G, Chiarenza A, Bulian P, Visco C, Mauro FR, Morabito F, Cortelezzi A, Zaja F, Forconi F, Laurenti L, Del Giudice I, Gentile M, Vincelli I, Motta M, Coscia M, Rigolin GM, Tedeschi A, Neri A, Marasca R, Perbellini O, Moreno C, Del Poeta G, Massaia M, Zinzani PL, Montillo M, Cuneo A, Gattei V, Foà R, Gaidano G. Molecular prediction of durable remission after first line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. *Blood*. 2015; 126:1921-4.

69. Mauro FR, Chauvie S, Paoloni F, Biggi A, Cimino G, Rago A, Gentile M, Morabito F, Coscia M, Bellò M, Sacchetti GM, Rossi D, Laurenti L, Autore F, Campanelli M, Trastulli F, Nicolai E, Riminucci M, Gaidano G, Guarini A, Gallamini A, Foà R. Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia (CLL) and progressive disease. *Leukemia*. 2015; 29:1360-5.
70. Audrito V, Serra S, Brusa D, Mazzola F, Arruga F, Vaisitti T, Coscia M, Maffei R, Rossi D, Wang T, Inghirami G, Rizzi M, Gaidano G, Garcia JG, Wolberger C, Raffaelli N, Deaglio S. Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia. *Blood*. 2015; 125:111-23.
71. Vaisitti T, Audrito V, Serra S, Buonincontri R, Sociali G, Mannino E, Pagnani A, Zucchetto A, Tissino E, Vitale C, Coscia M, Usai C, Pepper C, Gattei V, Bruzzzone S, Deaglio S. The enzymatic activities of CD38 enhance CLL growth and trafficking: implications for therapeutic targeting. *Leukemia* 2015; 29:356-68.
72. Foglietta M, Castella B, Mariani S, Coscia M, Godio L, Ferracini R, Ruggeri M, Muccio V, Omedé P, Palumbo A, Boccadoro M, Massaia M. The bone marrow of myeloma patients is steadily inhabited by a normal-sized pool of functional regulatory T cells irrespective of the disease status. *Haematologica*. 2014; 99:1605-10.
73. Montillo M, Tedeschi A, Gaidano G, Coscia M, Petrizzi VB, Orlandi E, Cascavilla N, Ghia P, Motta M, Gallamini A, Frustaci AM, Rossi D, De Paoli L, Nichelatti M, Morra E, Massaia M. Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients. *Haematologica*. 2014; 99:159-61.
74. Rizzo R, Audrito V, Vacca P, Rossi D, Brusa D, Stignani M, Bortolotti D, D'Arena G, Coscia M, Laurenti L, Forconi F, Gaidano G, Mingari MC, Moretta L, Malavasi F, Deaglio S. HLA-G is a component of the chronic lymphocytic leukemia escape repertoire to generate immune suppression: impact of the HLA-G 14 base pair (rs66554220) polymorphism. *Haematologica*. 2014; 99:888-96.
75. Mauro FR, Molica S, Laurenti L, Cortelezzi A, Carella AM, Zaja F, Chiarenza A, Angrilli F, Nobile F, Marasca R, Musolino C, Brugiattelli M, Piciocchi A, Vignetti M, Fazi P, Gentile G, De Propriis MS, Della Starza I, Marinelli M, Chiaretti S, Del Giudice I, Nanni M, Albano F, Cuneo A, Guarini A, Foà R; Gruppo Italiano Malattie Ematologiche dell'Adulto Working Party for Chronic Lymphoproliferative Disorders. Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile. *Leuk Res*. 2014; 38:198-203.
76. Arruga F, Gizdic B, Serra S, Vaisitti T, Ciardullo C, Coscia M, Laurenti L, D'Arena G, Jaksic O, Inghirami G, Rossi D, Gaidano G, Deaglio S. Functional impact of NOTCH1 mutations in chronic lymphocytic leukemia. *Leukemia*. 2014; 28:1060-70.
77. D'Arena G, Laurenti L, Coscia M, Cortelezzi A, Chiarenza A, Pozzato G, Vigliotti ML, Nunziata G, Fragasso A, Villa MR, Grossi A, Selleri C, Deaglio S, La Sala A, Del Poeta G, Simeon V, Aliberti L, De Martino L, Giudice A, Musto P, De Feo V. Complementary and alternative medicine use in patients with chronic lymphocytic leukemia: an Italian multicentric survey. *Leuk Lymphoma*. 2014; 55:841-7.

78. Brusa D, Serra S, Coscia M, Rossi D, D'Arena G, Laurenti L, Jaksic O, Fedele G, Inghirami G, Gaidano G, Malavasi F, Deaglio S. The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia. *Haematologica*. 2013; 98:953-63.
79. Coscia M, Vitale C, Peola S, Foglietta M, Rigoni M, Griggio V, Castella B, Angelini D, Chiaretti S, Riganti C, Guarini A, Drandi D, Ladetto M, Bosia A, Foà R, Battistini L, Boccadoro M, Fournié JJ, Massaia M. Dysfunctional V $\gamma$ 9V $\delta$ 2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells. *Blood*. 2012; 120:3271-9.
80. Serra S, Horenstein AL, Vaisitti T, Brusa D, Rossi D, Laurenti L, D'Arena G, Coscia M, Tripodo C, Inghirami G, Robson SC, Gaidano G, Malavasi F, Deaglio S. CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death. *Blood*. 2011; 118:6141-52.
81. Castella B, Riganti C, Fiore F, Pantaleoni F, Canepari ME, Peola S, Foglietta M, Palumbo A, Bosia A, Coscia M, Boccadoro M, Massaia M. Immune modulation by zoledronic acid in human myeloma: an advantageous cross-talk between V $\gamma$ 9V $\delta$ 2 T cells,  $\alpha\beta$  CD8+ T cells, regulatory T cells, and dendritic cells. *J Immunol*. 2011; 187:1578-90.
82. Castella B, Vitale C, Coscia M, Massaia M. V $\gamma$ 9V $\delta$ 2 T cell-based immunotherapy in hematological malignancies: from bench to bedside. *Cell Mol Life Sci*. 2011; 68:2419-32.
83. Coscia M, Pantaleoni F, Riganti C, Vitale C, Rigoni M, Peola S, Castella B, Foglietta M, Griggio V, Drandi D, Ladetto M, Bosia A, Boccadoro M, Massaia M. IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells. *Leukemia*. 2011; 25:828-37.
84. Coscia M, Quaglino E, Iezzi M, Curcio C, Pantaleoni F, Riganti C, Holen I, Mönkkönen H, Boccadoro M, Forni G, Musiani P, Bosia A, Cavallo F, Massaia M. Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. *J Cell Mol Med*. 2010; 14:2803-15.
85. Mariani S, Hwang SY, Foglietta M, Bonello L, Vitale C, Coscia M, Fiore F, Bruno B, Massaia M. Comprehensive assessment of the TCRBV repertoire in small T-cell samples by means of an improved and convenient multiplex PCR method. *Exp Hematol*. 2009; 37:728-38.
86. Biragyn A, Coscia M, Nagashima K, Sanford M, Young HA, Olkhanud P. Murine beta-defensin 2 promotes TLR-4/MyD88-mediated and NF-kappaB-dependent atypical death of APCs via activation of TNFR2. *J Leukoc Biol*. 2008; 83:998-1008.
87. Piva R, Ruggeri B, Williams M, Costa G, Tamagno I, Ferrero D, Gai V, Coscia M, Peola S, Massaia M, Pezzoni G, Allievi C, Pescalli N, Cassin M, di Giovine S, Nicoli P, de Feudis P, Strepponi I, Roato I, Ferracini R, Bussolati B, Camussi G, Jones-Bolin S, Hunter K, Zhao H, Neri A, Palumbo A, Berkers C, Ovaa H, Bernareggi A, Inghirami G. CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. *Blood*. 2008; 111:2765-75.

88. Matta GM, Battaglio S, Dibello C, Napoli P, Baldi C, Ciccone G, Coscia M, Boccadoro M, Massaia M. Polyclonal immunoglobulin E levels are correlated with hemoglobin values and overall survival in patients with multiple myeloma. *Clin Cancer Res.* 2007; 13:5348-54.
89. Fiore F, Nuschak B, Peola S, Mariani S, Muraro M, Foglietta M, Coscia M, Bruno B, Boccadoro M, Massaia M. Exposure to myeloma cell lysates affects the immune competence of dendritic cells and favors the induction of Tr1-like regulatory T cells. *Eur J Immunol.* 2005;35: 1155-63.
90. Mariani S, Muraro M, Pantaleoni F, Fiore F, Nuschak B, Peola S, Foglietta M, Palumbo A, Coscia M, Castella B, Bruno B, Bertieri R, Boano L, Boccadoro M, Massaia M. Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma. *Leukemia.* 2005; 19:664-70.
91. Coscia M, Biragyn A. Cancer immunotherapy with chemoattractant peptides. *Semin Cancer Biol.* 2004; 14:209-18.
92. Biragyn A, Ruffini PA, Coscia M, Harvey LK, Neelapu SS, Baskar S, Wang JM, Kwak LW. Chemokine receptor-mediated delivery directs self-tumor antigen efficiently into the class II processing pathway in vitro and induces protective immunity in vivo. *Blood.* 2004; 104:1961-9.
93. Coscia M, Kwak LW. Therapeutic idiotype vaccines in B lymphoproliferative diseases. *Expert Opin Biol Ther.* 2004; 4:959-63.
94. Ruffini PA, Biragyn A, Coscia M, Harvey LK, Cha SC, Bogen B, Kwak LW. Genetic fusions with viral chemokines target delivery of nonimmunogenic antigen to trigger antitumor immunity independent of chemotaxis. *J Leukoc Biol.* 2004; 76:77-85.
95. Coscia M, Mariani S, Battaglio S, Di Bello C, Fiore F, Foglietta M, Pileri A, Boccadoro M, Massaia M. Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy. *Leukemia.* 2004; 18:139-45.
96. Mariani S, Coscia M, Even J, Peola S, Foglietta M, Boccadoro M, Sbaiz L, Restagno G, Pileri A, Massaia M. Severe and long-lasting disruption of T-cell receptor diversity in human myeloma after high-dose chemotherapy and autologous peripheral blood progenitor cell infusion. *Br J Haematol.* 2001; 113:1051-9.
97. Besostri B, Beggiato E, Bianchi A, Mariani S, Coscia M, Peola S, Foglietta M, Boccadoro M, Pileri A, Moretta L, Massaia M. Increased expression of non-functional killer inhibitory receptor CD94 in CD8+ cells of myeloma patients. *Br J Haematol.* 2000; 109:46-53.
98. Coscia M, Massaia M. Active specific immunotherapy in human myeloma after high-dose chemotherapy. *Reviews in Clinical and Experimental Hematology.* 1999; 9:40-56.
99. Massaia M, Borrione P, Battaglio S, Mariani S, Beggiato E, Napoli P, Voena C, Bianchi A, Coscia M, Besostri B, Peola S, Stiefel T, Even J, Novero D, Boccadoro M, Pileri A. Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. *Blood.* 1999; 94:673-83.



## ADDITIONAL IN EXTENSO PUBLICATIONS


1. Vitale C, Coscia M. Aspetti biotecnologici delle immunoterapie con cellule CAR T. Progressi in Ematologia/1 2019.
2. Salvetti C, Santambrogio E, Orsucci L, Vitolo U, Coscia M, Vitale C. Idelalisib nei pazienti con leucemia linfatica cronica e linfoma follicolare: esperienza monocentrica real life. Eur J Oncol. 2017;22(1-S):11-16.
3. Vitale C, Coscia M. Trattamento con idelalisib e rituximab di un paziente con leucemia linfatica cronica e anemia emolitica autoimmune refrattaria. Quaderni di Ematologia clinica. Anno IV – Numero 1/2016.
4. Massaia M, Fiore F, Castella B, Pantaleoni F, Mariani S, Peola S, Hwang SY, Matta G, Foglietta M, Coscia M, Boccadoro M. Unconventional properties of zoledronic acid. Haematologica Reports. 2006; 2(7):106-108.
5. Mariani S, Pantaleoni F, Peola S, Hwang SY, Castella B, Matta G, Foglietta M, Fiore F, Coscia M, Boccadoro M, Massaia M. Distribution of  $\gamma\delta$  T cells in patients with hematological malignancies. Haematologica Reports. 2006; 2(3):32-34.
6. Coscia M, Quaglino E, Curcio C, Pantaleoni F, Forni G, Massaia M. Zoledronic acid impairs mammary carcinogenesis in BALB/c mice transgenic for the Her-2/neu oncogene. Haematologica Reports 2006; 2(3):37-38.
7. Coscia M, Massaia M. Active specific immunotherapy in human myeloma after high-dose chemotherapy. Reviews in Clinical and Experimental Hematology. 1999; 9:40-56.

## Bibliography

- Author or co-author in 96 peer reviewed articles and 7 *in extenso* publications.
- Coauthor in  $\approx$ 150 abstracts at National and International meetings and conferences.
- Speaker at >70 National and International meetings and conferences (including the Annual Meeting and Exposition of the American Society of Hematology and the Congress of the European Haematology Association).

Torino, June 7th 2022

Dr. Marta Coscia



Autorizzo il trattamento dei miei dati personali presenti nel curriculum vitae ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 e del GDPR (Regolamento UE 2016/679)